Grade @ adverse events with more than @ % incidence were fatigue ( @ % ) , decreased neutrophils ( @ % ) , decreased leukocytes ( @ % ) , and decreased platelets ( @ % ) for sunitinib and fatigue ( @ % ) for placebo ; grade @ adverse events were GI hemorrhage ( n = @ ) and pancreatitis , hypocalcemia , and elevated lipase ( n = @ ; all in same patient ) for sunitinib and thrombocytopenia ( n = @ ) and hypernatremia ( n = @ ) for placebo .